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2ABSTRACT. Glycol chitosan nanogels have been widely used in gene, drug and contrast agent 
delivery in an effort to improve disease diagnosis and treatment. Herein, we evaluate the 
internalisation mechanisms and intracellular fate of previously described glycol chitosan 
nanogels decorated with folate to target the folate receptor. Uptake of the folate decorated 
nanogel was impaired by free folate, suggesting competitive inhibition and shared internalisation 
mechanisms via the folate receptor. Nanogel uptake was shown to occur mainly through flotillin-
1 and Cdc42-dependent endocytosis. This was determined by inhibition of uptake reduction 
observed upon siRNA depletion of these two proteins and the pathways that they regulate. The 
data also suggest the involvement of the actin cytoskeleton in nanogel uptake via 
macropinocytosis. After 7 h of incubation with HeLa cells, approximately half of the nanogel 
population was localised in endolysosomal compartments, while the remaining 50% of the 
material was in undefined regions of the cytoplasm. Glycol chitosan nanogels may thus have 
potential as drug delivery vectors for targeting different intracellular compartments. 
1. Introduction
Macromolecular micelles, commonly termed nanogels, have been synthesised, characterised and 
studied for numerous biomedical applications including delivery of therapeutic entities. Active 
nanogel targeting strategies have been conceived to enhance their site-specific delivery by, for 
example, decorating the surface with ligands of plasma membrane receptors that are over-
expressed on target cells 1.
A major advantage in the use of nanoparticles as drug delivery systems lies in their amenability 
to modifications that allow them to cross biological barriers. The cell membrane is naturally 
impermeable to complexes larger than 1 kDa, however, nanoparticle uptake may occur through a 
variety of active endocytic mechanisms, which depend on the physicochemical features of the 
3nanoparticle and the nature of the target cells. For the successful development of nanocarriers it 
is crucial to understand the molecular mechanisms involved in their interactions with the cell 
membrane, in addition to their entry via endocytic pathways and subsequent intracellular fate  2-4. 
Generally, endocytosis can be divided into two broad categories: phagocytosis (uptake of large 
particles) and pinocytosis (uptake of fluids, solutes and also ligands via plasma membrane 
receptors). Phagocytosis is characteristic of specialised professional phagocytes, while 
pinocytosis is present in virtually all cells and has multiple forms depending on the cell origin 
and function 5. Several different classifications for pinocytosis have been proposed, and a 
common approach is to order according to the key proteins involved: clathrin-mediated 
endocytosis (CME), caveolae-mediated endocytosis (CvME), clathrin- and caveolae-independent 
endocytosis and macropinocytosis. Clathrin- and caveolae-independent pathways can be further 
sub-classified as Arf6-dependent, flotillin-1-dependent, Cdc42-dependent and RhoA-dependent 
endocytosis 5-9.
The uptake mechanism of a drug delivery system is likely to influence its intracellular fate and 
capacity to mediate a biological response. The aim of the present study was to identify the 
endocytic mechanisms responsible for the internalisation of glycol chitosan nanogels 
functionalised with folate in HeLa (cervical adenocarcinoma) cells that overexpress folate 
receptors 10. Conventionally, chemical endocytosis inhibitors have been used to analyse cellular 
uptake of drug delivery vectors including chitosan nanoparticles, but these inhibitors are 
associated with problems related to toxicity and low specificity 11-13.  Selective inhibition of 
different endocytic pathways can also be attempted by siRNA-targeting and subsequent 
depletion of key proteins that orchestrate individual pathways 14, 15.
4In this work, single siRNA sequences were used to attenuate pathways regulated by clathrin 
heavy chain (si-CHC), caveolin-1 (si-Cav-1), p21-activated kinase 1 (si-Pak-1), Flotillin-1 (si-
Flot-1) 14 and Cdc42 (si-Cdc42).  These cells were then used to determine the mechanism of 
uptake and intracellular fate of the nanogels to provide valuable information regarding their 
capacity to deliver different types of cargos.
2. Experimental
2.1. Reagents
Glycol Chitosan (GC, G7753), mercapto hexadecanoic acid (MHDA), N-
hydroxysulfosuccinimide (NHS), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC), O-methyl-O’-succinylpolyethyene glycol 2000 (PEG2000), O-(2-
Aminoethyl)-O’-(2-carboxyethyl)polyethylene glycol 3000 hydrochloride (PEG3000), folate, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and sulforhodamine B 
(SRB) were purchased from Sigma (St. Louis, MO, US). Folate-free RPMI 1640 medium, Opti-
MEM, oligofectamine, Alexa Fluor® 647 Dextran 10.000 MW (Alexa647-Dextran), Alexa 
Fluor® 647 transferrin (Alexa647-transferrin), Alexa Fluor® 488 carboxylic acid (succinimidyl 
ester) were bought from Invitrogen (Carlsbad, CA, USA). Complete mini protease inhibitor 
cocktail tablets were from Roche Diagnostics (Mannheim, Germany). Single siRNA sequences 
of 21-23 residues were acquired from Europhins MWG Operon (Ebesburg, Germany) as 
previously described 14. 
2.2. Antibodies
5Antibodies recognizing Clathrin Heavy Chain was from NeoMarker (California, US); Anti-Cav-
1 was from Cell signalling Technology (Hertfordishire, UK); Anti-Pak-1 was from Cell 
Signaling (Danvers, Massachusetts, US) and antibody to Flot-1 was from BD Bioscience 
(Oxford, UK); Anti-g-tubulin was from Sigma (Dorset, UK).  Secondary goat anti-mouse- and 
goat anti-rabbit- HRP were from Pierce (Loughborough, UK).
2.3. Cell culture
HeLa cancer cells were cultured in DMEM supplemented with 10 % foetal bovine serum (FBS), 
100 IU/mL penicillin and 0.1 mg/mL streptomycin. The cells were maintained as a subconfluent 
monolayer in a humidified atmosphere containing 5 % CO2 at 37 ºC.
2.4. Self-assembly of nanogels
Details of Glycol Chitosan nanogel synthesis and characterisation as folic acid functionalised 
nanogels were described in a previous report16. Briefly: nanogel synthesis was performed in two 
independent steps. Initially, folate is conjugated to PEG3000 (FA-PEG3000). In the second 
reaction, FA-PEG3000, PEG2000 and MHDA were grafted onto the GC polymer. The nanogel 
dispersions used in the different experiments were obtained after dispersing the lyophilised 
reaction product in distilled water, under magnetic stirring at 50 ºC for 48 h, and passing through 
a pore size 0.45 m cellulose acetate syringe filter.
2.5. Preparation of the Alexa Fluor® 488 labelled nanogel
The nanogels were labelled with Alexa Fluor® 488 carboxylic acid (succinimidyl ester) through 
an amide linkage. The Alexa488 was dissolved in DMSO. The molar ratio of Alexa488 
6carboxylic groups to the nanogel free amine groups was 0.11. The dye was added to nanogel 
dispersions at 1 mg/mL in PBS and incubated in the dark at room temperature for 24 h. 
Thereafter, the reaction mixture was extensively dialysed (MW cutoff 10-12 kDa) against 
distilled water to remove free Alexa488. To verify the absence of free dye, the conjugated 
Alexa488-nanogel was purified by centrifugation at 3,000 x g through a 10 kDa MW cut-off 
filter.
2.6. Cellular uptake of nanogels by flow cytometry
HeLa cells were seeded onto 24-well plates at 2.0x105 cells per well and left to adhere overnight. 
The cells were treated with nanogels at 0.2 and 0.4 mg/mL for 0, 1, 3, 7 and 24 h. After each 
time point the mixture, the culture medium and nanogels suspensions were removed and the cells 
were washed with PBS and collected using 150 L of trypsin/EDTA (0.25%/0.02%) in PBS 2 
min at 37 ºC; after addition of FBS supplemented medium the cell suspension was centrifuged at 
300 x g for 10 min and rinsed with PBS.  The cell associated fluorescence was measured by flow 
cytometry using a Coulter Epics XL Flow Cytometer (Beckman Coulter Inc., Miami, FL, USA). 
2.7. siRNA transfection 
The transfections were performed as described by Soraj et al. 14. Briefly: cells were seeded in 
antibiotic-free medium at a density of 1.6x105 cells in a 35 mm glass bottomed imaging dish 
(MatTek, Ashland, USA) and per well in a 6-well plate.  For 12-well plates the density was 
reduced to 6.7x104 cells per well. The cells were cultured overnight to obtain the desirable 
confluency at the beginning of the transfection (~60%). The siRNA transfection procedure was 
adjusted according to well diameter. Volumes used for a 12-well plate were: 0.5 L of 50 M of 
7stock siRNA diluted in 89.5 L of Opti-MEM and 2.0 L of oligofectamine in 8.0 L of Opti-
MEM. The diluted solutions were then gently mixed and stored at room temperature for 30 min. 
For each well, the media was removed and replaced with 400 L of Opti-MEM. The complex 
siRNA-oligofectamine was added dropwise to the wells and incubated at 37 ºC and 5 % CO2 for 
4 h. Thereafter 250 L of Opti-MEM containing 30 % (v/v) of FBS was added to the transfection 
mixture and the cells were incubated under tissue culture conditions for 48 h. 
2.8. In vitro viability of the transfected cells 
MTT assay
The effect of siRNA transfection on cell metabolic activity was evaluated using the quantitative 
colorimetric MTT assay. The cells were seeded onto 24-well cell culture plates at a density of 
3.4x104 cells per well and transfected with the different siRNAs as described above. After the 
transfection period (48 h) cell metabolic activity was measured by adding MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 17. The MTT solution (0.5 mg/mL in 
PBS) was carefully removed from each well and the resulting dark blue formazan crystals were 
solubilised in dimethyl sulfoxide and quantified spectrophotometrically at 570 nm. A reference 
absorbance at 690 nm was measured for the purposes of background subtraction. 
Sulforhodamine B assay
Cell proliferation of the siRNA transfected cells was assessed using the Sulforhodamine B (SRB) 
assay, which provides an estimate of total protein which in turn is related to cell number 18, 19. 
After transfecting cells with siRNAs for 48 h, 24-well plates were rinsed with PBS and left to dry 
at 37 ºC, 5 % CO2. Ice cold 1% acetic acid: 100% methanol solution was then used to fix the 
8cells at -20 ºC for 30 min. After discarding the fixative solution the plates were left dry at 37 ºC 
before adding 250 L of 0.5 % of SRB in 1 % acetic acid to each well. Ninety minutes later the 
cells were 4x washed with 1 % of acetic acid to remove the excess Sulforhodamine B and then 
left dry. 1.0 mL of 10 mM Tris solution was used to dissolve the Sulforhodamine. The 
supernatant was used for quantification of SRB protein staining that was quantified by a 
spectrophotometer at 540 nm. 
2.9. Nanogel internalisation in endocytosis compromised cells 
2.9.1. Fluorescence microscopy
Live cell imaging via confocal microscopy
siRNA-transfected cells, 48 h post transfection (Section 2.7) in glass-bottomed 35 mm culture 
dishes were incubated with nanogels at 0.2 mg/mL for 7 h. The cells were then rinsed 
extensively with PBS and immediately imaged as live cells in phenol red free-DMEM by 
confocal microscopy at 37 ºC on a Leica SP5 system, as previously described 14. Control and 
CHC depleted cells, were also incubated for 16 min with the CME probe Alexa647-transferrin 
(50 nM) to evaluate the efficiency of transfection.
Immnunolabelling
Cav-1 depletion was confirmed by immunolabelling and confocal microscopy. At the end of the 
transfection the cells on glass coverslips were rinsed with PBS and fixed with 3 % PFA for 15 
min at room temperature. Then the samples were treated with 50 mM of PBS/NH4 for 10 min to 
quench reactive species resulting from fixation. After 3x PBS washing the cells were 
permeabilised with PBS/0.2 % Triton X-100, washed and immersed in blocking buffer, 2 % (v/v) 
9foetal calf serum and 2 % (w/v) BSA in PBS, for 30 min. Cells were then incubated with the 
primary antibody recognizing Cav-1 and subsequently with secondary Alexa546 labelled 
antibody. The cells were finally incubated in Hoechst 33342 for 10 min at room temperature to 
label the nucleus. Finally, the coverslips were mounted on glass sides and the cells were 
visualised by confocal microscopy. Cells were imaged through the z-axis to generate z-
projection images.
2.9.2. Flow cytometry 
Quantification of cell associated fluorescence in siRNA transfected cells following incubation 
with nanogel was performed by flow cytometry. For this, siRNA transfected cells in a 12-well 
plate were incubated with Alexa488-nanogel (0.2 mg/mL) for 7 h under tissue culture conditions. 
The cells were then thoroughly washed with PBS, trypsinised with trypsin/EDTA 0.25%/0.02% 
in PBS for 2 min at 37ºC; after addition of FBS supplemented medium the cell suspension was 
centrifuged at 300 x g for 10 min. The cell suspension was washed with PBS. Cell-associated 
fluorescence of the cell suspension was measured using a Coulter Epics XL Flow Cytometer 
(Beckman Coulter Inc., Miami, FL, USA).    
2.9.3. SDS page and Western blotting
Following 48 h of siRNA transfection, the cells from 6 well plates were washed in ice-cold PBS 
and collected on ice by scraping in 100 L of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, pH 
8.0, 1 % Triton X-100), containing protease inhibitor cocktail. Lysates were then centrifuged at 
13,000 x g (4 ºC) for 10 min before adding three parts supernatant to one part 4x Laemmli 
buffer. The samples were heated at 95 ºC for 5 min and centrifuged at 13,000 x g (4 ºC) for 1 
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min prior to loading (18 g of protein per well) onto 10 % acrylamide gels for separation by 
SDS-PAGE.  Following electrophoresis the separated proteins were transferred to PVDF 
membranes that were rinsed with PBS and blocked in 5 % milk in PBS Tween 20 (0.025%; 
PBST) for 1 h. The membranes were then probed with antibodies recognising CHC, Cav-1, Pak-
1, Flot-1, g-tubulin and b-actin diluted in 2 % milk in PBST.  Following washing in PBST, 
species specific secondary antibodies conjugated to horseradish peroxidase (HRP) and diluted in
2 % milk in PBST were applied to the membrane. Protein bands were detected by Enhanced 
Chemiluminescence (ECL). 
2.10. Nanogel intracellular localisation
HeLa cells were seeded at 3x105 cells in glass bottom dishes and left to adhere overnight. 0.2 
mg/mL of the Alexa488-nanogel and 0.025 mg/mL of Alexa647-Dextran were then co-incubated 
with cells for 7 h in folic acid free medium. In the case of Alexa488-nanogels co-incubation with 
Alexa647- transferrin (50 nM) was performed by adding transferrin 16 min before the end of the 
nanogel incubation period (7 h). The cells were extensively rinsed with PBS and immediately 
imaged as live cells in phenol red free-DMEM by confocal microscope at 37 ºC.
2.11. Statistical analysis
Results are expressed as mean ± S.D. of three independent experiments, each one with n=3.  
Statistical significances were determined by applying a one-way ANOVA with a Dunnett’s 
Multiple comparison test through Prism software (GraphPad software version 5.00, USA).
Significance of the results is indicated according to p values * p<0.05, ** p<0.005 and *** 
p<0.0001.  
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3. Results and Discussion
We have previously shown folate functionalised glycol-chitosan nanogel have increased uptake 
over the unfunctionalised nanogels 16.  Herein we investigate the uptake and internalisation 
properties of the folate functionalised nanogels.
3.1. Cellular uptake of nanogels as a function of time, concentration and presence of folate  
We examined the effects of folic acid functionalised nanogel concentration and the presence of 
folate in the culture medium on the internalisation of Alexa488-nanogel at different time points. 
HeLa cells were incubated for different time periods with the fluorescent nanogels at 
concentrations of 0.2 and 0.4 mg/mL in media either depleted of, or containing folate. Cells were 
collected and the mean fluorescence intensity (a proxy for nanogel uptake) was measured by 
flow cytometry.
Figure 1 (A) shows that nanogel uptake increases with time over a 24 hour period in cells 
incubated with 0.4 mg/mL nanogel. However, in cells incubated with 0.2 mg/mL nanogel, uptake 
increases over the first 7 h but then at some time during the 7-24 h incubation period the mean 
fluorescence intensity decreases.  The data indicate not only reduced uptake at this lower 
concentration but also a loss of the nanogel from the cells.  This suggests that during longer 
incubation periods (7 h+) at this concentration the fluorescently labelled nanogel may either be 
recycled out of the cell or degraded.  Degradation would seem more likely as recycling would 
potentially lead to reuptake of the nanogel and as such we would expect to see stabilisation in the 
level of internalised nanogel rather than loss. 
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Figure 1B demonstrates that internalisation of the Alexa488-nanogel is significantly increased in 
folate-depleted culture conditions compared with culture in normal media. The presence of free 
folate in the culture medium has previously been shown to lead to a decrease in uptake of folate-
conjugated nanoparticles by cells overexpressing folate receptors 7, 20. Viewed in this context we 
suggest that the folate receptors may be involved in the internalisation of the Alexa488-nanogel, 
although other non-specific mechanisms may also contribute to the uptake. To eliminate the 
inhibitory and potentially confounding effects of folate in the media, folate was eliminated from 
subsequent uptake experiments. 
Figure 1. Effects of nanogel concentration (A) and the presence of folate in the culture medium 
(B) on the internalisation of Alexa488-nanogel at different time points in HeLa cells. Mean 
fluorescence intensity (MFI) was used as a proxy for fluorescent nanogel uptake and was 
measured by flow cytometry at various time points up to 24 h (A) and 7 h (B).  
3.2. Inhibition of endocytic pathways through siRNA depletion of endocytic proteins 
3.2.1. Viability of siRNA-transfected cells
The mechanism of nanogel internalisation was studied using siRNA transfection as a tool to 
silence endocytic proteins and inhibit distinct endocytic pathways. It is known that the level of 
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cellular toxicity caused by transfection is dependent on the reagent used and on the nature of the 
cells. Cell proliferation and metabolic activity of HeLa cells transfected using oligofectamine 
were studied to ensure that the viability was not compromised by the procedure. The metabolic 
activity of HeLa cells was not significantly affected by transfection (Figure 2, A). Although 
statistically significant differences were detected in total protein levels, these are relatively small 
and unlikely to be of biological significance (Figure 2, B). 
Figure 2. Effect of the si-RNA transfection on metabolic activity and total protein mass of HeLa 
cells assed by the MTT (A) and sulforhodamine (B) assays. * p<0.05 or *** p<0.001 represent 
14
the statistical significance of differences in viability between non-transfected cells and the 
siRNA depleted samples. The results were expressed as mean ± SD.
3.2.2. Cellular uptake mechanism(s) of the nanogels by endocytosis compromised cells
Inhibition of clathrin mediated endocytosis (CME)
Clathrin-mediated endocytosis (CME) is the best characterised mechanism of endocytosis and 
requires the Adaptor-2 complex in association with clathrin heavy and light chain 7, 8. Cargos 
taken up by clathrin-coated vesicles follow the classical endocytic pathway to early endosomes 
where sorting occurs for delivery to other organelles such as the lysosomes or back to the cell 
surface through recycling endosomes13. The uptake and recycling of transferrin occurs through 
this endocytic pathway, hence this protein is commonly used as a marker to detect interference 
with CME 14, 21. CHC is the major coat protein associated to this internalisation pathway 7; thus 
in the present study si-CHC transfected HeLa cells were incubated with Alexa647-transferrin to 
evaluate the efficiency of CME inhibition. Transferrin uptake in clathrin depleted cells was 
visibly lower compared with non-transfected and si-GFP transfected cells (Figure 3, A), 
reflecting successful and population-wide transfection. CHC depletion was directly confirmed 
through CHC expression analyses in cell lysates (Figure 3, B). In order to ascertain if the nanogel 
utilises this internalisation pathway, si-CHC transfected HeLa cells and the respective controls 
were incubated with nanogels and then analysed via confocal microscopy (Supplementary Figure 
1) and flow cytometry (Figure 3, C) revealed no differences in nanogel uptake between control 
cells and those deficient in CME suggesting that this pathway is not involved in nanogel uptake.
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Figure 3. CME inhibition in HeLa cells. (A) Confocal visualisation of HeLa cells transfected 
with si-CHC or si-GFP control for 48 h prior to incubation with Alexa647-transferrin for 16 min. 
For each condition (rows) the images correspond to (left to right) maximum projection, middle z 
section through the cells and Differential Interference Contrast (DIC) images. The scale bars 
represent 25 m. (B) CHC expression after transfecting HeLa cells with si-CHC for 48 h. (C) 
Effect of the CME silencing on nanogel cellular uptake expressed as mean fluorescence intensity 
(MFI). Error bars represent S.D.
Inhibition of caveolae-mediated endocytosis (CvME)
CvME starts with the formation of caveolae on the plasma membrane of cells, often in lipid rafts. 
Caveolae are noted as being enriched in the protein Cav-1 and have a diameter between 50-100 
nm. A dynamin dependent scission of the caveolae from the membrane then results in the 
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formation of the endosome-like caveosome 8. Initially the caveosome interior was thought not to 
acidify to any great extent with delivery  of cargo to the Golgi and/or endoplasmic reticulum, 
thus avoiding the lysosomal degradation 8. However, Chiu et al. 22 revealed that N-palmitoyl 
chitosan nanoparticles enter cells via caveolae and were transiently localised in caveosomes 
before trafficking to the canonical endosomal pathway en route to lysosomes. Agents, such as 
viruses, that are taken up by caveolae are also thought to end up in endosomes that can be 
directed to lysosomes. Evidence from electron microscopy studies suggest that caveosomes 
represent a special type of caveolar endosome that always associates with the plasma membrane  
23. The theory behind the existence of caveosomes mostly results from studies which involve 
caveolin overexpression or caveolin mutants and as such may or may not be a naturally 
occurring phenomenon 23. 
CvME inhibition was achieved through depletion of Cav-1 using transfection with si-Cav-1. 
Since Cav-1 is a critical component of caveolae formation at the plasma membrane 8,its 
depletion results in the impairment of CvME. The efficiency of siRNA transfection was 
visualised by immunofluorescence microscopy of Cav-1, since a reliable endocytic marker 
equivalent to transferrin for CME, for assessing uptake via caveolae has not yet been identified. 
As shown in Figure 4 (A) a decrease in caveolin vesicle labelling was clearly observed in si-Cav-
1 transfected cells. Significant Cav-1 depletion was also confirmed through Western blot 
analysis of cell lysates (Figure 4, B). 
There is data to suggest that folate internalisation through the folate receptor occurs via CvME 3. 
For example, folate-targeted poly(ethylene glycol) (PEG)-coated nanoparticles were thought to 
internalise via caveolae-assisted endocytosis and the nanoparticles were subsequently visualised 
in punctate structures 24. Conversely, internalisation and trafficking of folate receptors was found 
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not to be exclusively caveolae dependent: specifically, folate-protein conjugates after binding to 
folate receptors on the surface of cancer cells, irrespective of size, were internalised via uncoated 
pits or caveolae, however at later times (6 hours), some conjugates were found in lysosomes; so 
caveolae-mediated endocytic pathway converged with a pathway utilised by clathrin-coated pits. 
25. In agreement with this, as shown by confocal microscopy in supplementary Figure 2 and 
quantified by flow cytometry in Figure 4 (C), nanogel uptake was reduced, but not significantly 
(p³0.05), in Cav-1 depleted cells. However, it should be noted that when a particular route is 
inhibited others may become activated as a compensatory mechanism 22. For example, Cav-1 
depletion has been shown to result in increased levels of activated Cdc42 at the plasma 
membrane 5; this protein is thought to regulate the actin cytoskeleton and folate internalisation 
through the glycosylphosphatidylinositol (GPI)-anchored folate receptor 26. 
The hydrophobicity of the cargo may be a determining factor for its internalisation via CvME. 
The uptake of N-palmitoyl chitosan nanoparticles was associated with lipid raft-mediated 
endocytic routes, and substitution of chitosan with a higher level palmitoyl groups (>10 %) 
increased the fraction of nanogel uptake via CvME 22. 
Also noteworthy is the impact of nanogel size distribution on CvME and indeed on other 
pathways. The nanogels in this study have mean diameters of around 200 nm and size may play a 
critical role in their mechanism of uptake. To our knowledge no studies have unambiguously 
demonstrated that caveolae can accommodate particles larger than 100 nm and this has 
previously been noted 27. However, CvME was thought to play a major role in the cellular uptake 
of Chitosan/DNA/poly(g-glutamic acid) complexes with an average size of approximately 150 
nm 28.  It should be noted that most studies suggesting that caveolae are involved in the uptake of 
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drug delivery vectors rely on the use of chemical endocytosis inhibitors, which often influence 
more than one pathway12.
Figure 4. CvME inhibition in HeLa cells. (A) Control and si-Cav-1 or GFP treated cells, were 
fixed after 48 h, labelled with antibodies against Cav-1 and Alexa546 conjugated secondary 
antibody and then analysed by confocal fluorescence microscopy. Maximum projection (left) and 
a single z section (right) is shown to each condition; nuclei are labelled with Hoechst 33342. 
Scale bars represent 25 m. (B) Cav-1 expression after transfecting HeLa cells with si-Cav-1 for 
48 h. (C) Effect of the CvME inhibition on cellular uptake of nanogels expressed as mean 
fluorescence intensity (MFI).  Error bars represent S.D.
19
Inhibition of macropinocytosis
Macropinocytosis is a poorly characterised pathway that internalises extracellular material in the 
fluid-phase. This process involves, especially after growth factor activation, membrane ruffling 
and formation of relatively large vesicles, named macropinosomes. These are heterogeneous in 
size, generally considered larger than 0.2 µm and have no clearly identified and unique coat 
structures 29, 30. It is known that p21-activated kinase (Pak-1) is associated with growth factor 
induced macropinosomes 14 and can be activated by the small GTPases Cdc42 and Rac1 31. 
Whether the fate of macropinosomes inside the cells involves fusion with lysosomes or recycling 
to the plasma membrane, or a mixture of both, is unclear, and likely to be dependent on cell type 
8.
The addition of cationic molecules and particles to cells will inevitably result in interaction with 
the negative surface mediated by surface sugars 2, 3. This may or may not lead to internalisation 
via membrane turnover or activation of macropinocytosis through ruffling.  Membrane ruffling 
has been extensively studied in the field of cationic cell penetrating peptides 14, 30. In the present 
study we found that the cellular uptake of the positively charged nanogel (+ 25 mV)16, was 
significantly affected in Pak-1 depleted cells (Figure 5, A and B). 
Studies using chemical inhibitors in HeLa cells have suggested that macropinocytosis plays a 
crucial role in the internalisation of hydrophobically modified glycol chitosan nanoparticles 
(mean size 350 nm and positive surface charge, + 22 mV) 4. However, other uptake pathways 
were also thought to be involved in uptake of these nanoparticles.  
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Figure 5. Pak-1 depletion of HeLa cells. (A) Inhibition of nanogel cellular uptake, expressed as 
mean fluorescence intensity (MFI). ** represents statistical significance of p< 0.01 for 
differences in nanogel uptake between untransfected cells and si-Pak-1 transfected cells, error 
bars represent S.D.; (B) Pak-1 expression after transfecting HeLa cells for 48 h with control or 
si-Pak-1.  
Inhibition of clathrin- and caveolin-independent endocytosis: Cdc42 and flotillin dependent 
endocytosis
Nanoparticles and polymers modified with folate have been shown to bind to folate receptors 
that are often over-expressed in tumour cells 6, 32. These multiple glycophosphatidylinositol-
anchored proteins (GPI-Aps) are slowly internalised by cells and can be detected in a population 
of early endosomal organelles referred to as GPI-enriched early endosomal compartments, or 
GEECs. The uptake process is not blocked by perturbations of CME 26, 31. Cdc42-dependent 
endocytosis has been reported to be involved in the uptake of GPI-anchored proteins 23, and due 
to the actin mediated effects of Cdc42 it is also a well characterised regulator of 
macropinocytosis 29.  Raft-associated proteins flotillin -1 and flotillin-2 are also thought to play a 
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role in cellular uptake and trafficking mechanisms of nanoparticles. Flotillin-1 has been 
described as regulator of specific clathrin and caveolae-independent uptake mechanisms 15, 23. 
Furthermore, flotillins appear to play a general function in late- or lysosomal degradation or 
storage processes 33. 
In order to investigate whether the nanogel internalisation is affected by flotillin-1 and/or Cdc42-
dependent pathways, expression of these proteins in HeLa cells was siRNA-depleted prior to 
performing uptake assays. The results shown in Figure 6 (A) demonstrate that cellular uptake is 
significantly affected in these endocytosis compromised cells: nanogel uptake was inhibited by 
approximately 70% and 65% in cells depleted of flotillin-1 (Figure 6, B) or Cdc42, respectively.  
We are currently unable to label Cdc42 on membranes to investigate the extent of protein 
depletion but importantly, two different sequences targeting Cdc42 were shown to have almost 
identical effects on nanogel uptake.
Figure 6. (A) Flow cytometry analysis of the HeLa cells depleted of flot-1 or Cdc42 and 
incubated with Alexa488-nanogel by 7 h. Error bars represent S.D. *** indicates a statistical 
significance of p<0.001 for the differences in nanogel uptake between untransfected cells and the 
siRNA transfected cells.  Error bars represent S.D.; (B) Flotillin-1 expression after transfecting 
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HeLa cells for 48 h with siRNA targeting Flot-1.  CHC expression was measured as a loading 
control.  
The complete siRNA data presented in this study are summarised in Figure 7, highlighting that 
the nanogel internalisation appears to be dependent on multiple endocytic pathways. This has 
been previously reported for chitosan and chitosan derived nanoparticles using chemical 
inhibitors of endocytosis 13, 34. It remains to be determined whether the nanogel is actually 
entering via a flotillin or Cdc42 mediated pathway or even macropinocytosis, but it raises 
interesting questions regarding the effect of depletion of these proteins on the overall 
organisation of the plasma membrane. The effects of depletion of Cdc42 and Pak-1 also 
highlight the importance of the actin cytoskeleton and most probably macropinocytosis in the 
uptake of the nanogels.  We suggest that nanogels enter the cell through their activation of the 
cell membrane, promoting their own uptake via actin reorganisation and membrane ruffling. 
Further experiments are required to test this hypothesis more thoroughly.
Using siRNA to overcome the lack of specificity associated with traditional chemical inhibitors, 
we are able to more accurately target endocytic pathways utilised by the nanogel.  Different 
pathways can be utilised to direct cargo to various cellular destinations including the lysosomes, 
Golgi or exocytic structures for recycling. Overall, determining the uptake mechanism utilised by 
a nanoparticle can significantly aid in the understanding of the nanoparticle’s ability to perform 
its function and provide information for rational design of improved delivery systems.  
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Figure 7. Mean fluorescence intensity (MFI) of the nanogel internalised by HeLa cells 
transfected with si-CHC, si-Cav-1, si-Pak-1, si-Flot-1 and si-Cdc42, measured by flow 
cytometry. Untreated cells, cells incubated with oligofectamine alone or transfected with 
oligofectamine/si-GFP were tested as negative controls. 48 h post transfection the cells were 
incubated with nanogel, trypsinised and analysed by flow cytometry. ** p<0.01 or *** p<0.001 
represent the statistical significance of differences in nanogel between untransfected cells and the 
remaining samples. Error bars represent S.D.
3.3. Nanogel intracellular localisation 
Once the key mechanisms of nanogel internalisation had been identified, we aimed to investigate 
their intracellular fate by confocal laser scanning microscopy.  Determining the subcellular 
localisation of these vectors at different time points can give important information regarding 
their suitability for delivering therapeutic cargo into cells and specific subcellular compartments. 
For this, we made use of well-characterised endocytic probes whose mechanism of uptake is 
understood, as is their eventual cellular fate. The intracellular localisation of the Alexa488-
nanogel was compared with transferrin and dextran, both labelled with Alexa647.  By using 
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specific experimental conditions, these probes can be used to identify early, recycling and late 
endosomes as well as terminal lysosomes 21, 35.
When internalised, iron loaded holo-transferrin is trafficked via clathrin coated vesicles to early 
endosomes and then further directed to recycling endosomes, Finally, it is returned to the cell 
surface as apo-transferrin for another constitutive cycle of iron loading 21. To determine if the 
nanogels enter the same early/recycling endosomal compartment as transferrin we co-incubated 
the two compounds for the final 16 min of the 7 h nanogel uptake period prior to performing live 
cell confocal microscopy. This short period allows the transferrin to traffic to, and so label, early 
and recycling endosomes. The images and colocalisation data shown in Figure 8 (A-C) 
demonstrate that there is very little colocalisation between transferrin and the nanogel after they 
have entered the cell. This is expected based on data in Figure 3 and also the possibility that most 
of the nanogels have trafficked to other endocytic compartments that would be devoid of 
transferrin labelling, i.e. late endosomes and lysosomes.
To test whether the nanogel was in fact being trafficked via endolysosomal structures, 
nanogel/dextran co-incubation experiments were performed. These experiments revealed 
considerable colocalisation (~50%) between nanogel and dextran, as illustrated by co-
localisation of the two probes in distinct intracellular yellow dots Figure 8 (D-F). 
Cdc42 has also been shown to regulate fluid phase endocytosis and dextran enters cells via this 
mechanism 36.  Thus the inference from the data in Figure 8F, would be that the nanogel 
colocalised with the dextran represents the fraction of nanogel that enter the cell in a Cdc42 
dependent manner. This conclusion is strengthened by our findings in Figure 6 that Cdc42 is 
required for ~70% of nanogel uptake. The absence of complete colocalisation may be attributed 
to the fraction that enters the cell via lipid rafts and regulated by expression of flot-1. Previous 
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studies by other researchers have demonstrated a high extent of colocalisation between acidic 
organelles and hydrophobically modified glycol chitosan nanoparticles in HeLa H2B-GFP cells 
labelled with LysoTracker© Red probe 4. Other research using human renal proximal tubular 
KHC cells has shown that 50 % of positively charged chitosan based nanoparticles could escape 
from lysosomes and reach the cytosol, after 6 h of incubation 37.  Lower levels of colocalisation 
(~20%) of hydrophobically modified glycol chitosan nanoparticles/lysosomal vesicles labelled 
with LysoTracker© in HeLa cells has also been noted 34. 
Figure 8. Nanogel subcellular distribution in HeLa cells after 7h of incubation with (A-C) 
Alexa647-transferrin (16 min prior to analysis) or (D-F) Alexa647-Dextran (7 h co-incubation). 
The images correspond to single channel capture of nanogels (A,D, green in merge) transferrin 
(B, red in merge) and Dextran (E, red in merge) and respective merged images (C, F) Unfilled 
(A) (B) (C) 
(D) (E) (F) 
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arrows show single nanogel structures, filled arrows show single transferrin or dextran structures 
and arrowheads show colocalisation between nanogel and probe. Scale bars represent 15 m. 
The data from this study suggest that a fraction of nanogel may ultimately be delivered to 
lysosomes. This is not unexpected as pathways such as CME, caveolae and macropinocytosis 
have been shown to deliver some ligands and their receptors to lysosomes. However, because 
molecules such as transferrin can enter cells via CME but are recycled rather than degraded it 
remains to be determined what, if any, fraction of the nanogels recycles. The possibility exists 
that recycling could be mediated from late endocytic structures via a pathway that may be 
distinct from that used by transferrin.38
Although undesirable in many cases for therapeutic cargo that would be inactivated in lysosomes  
e.g. siRNA or DNA, specific lysosome targeting may be beneficial for drug delivery strategies to 
replace deficient lysosome enzymes to treat conditions such as lysosomal storage diseases 39. 
Beyond this, nanomedicines targeting the endolysosomal pathway also have potential for 
improving drug delivery to address other major disease burdens including  Alzheimer Disease 
and cancer 3, 37. 
4. Conclusions
Inhibition of endocytic pathways via siRNA depletion of specific endocytic proteins has 
provided new insights into the way that nanogel enters cells with respect to the requirements for 
specific proteins and the types of pathways that they orchestrate. 
The involvement of Cdc42 and Pak-1 strongly suggest that actin reorganisation is also required 
for uptake but whether this is constitutive or active macropinocytosis remains to be determined.  
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Colocalisation studies with endocytic probes showed that some of nanogel is delivered to 
endolysosomal compartments but a significant fraction was also in organelles that await further 
characterisation. 
Supporting Information available. 
Live cell confocal microscopy observation of Alexa488-nanogels incubated with si-CHC and si-
Cav-1 transfected cells. This material is available free of charge via the Internet at 
http://pubs.acs.org.” 
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Endocytic pathways and endocytic proteins regulating the uptake of therapeutic macromolecules. 
Broken arrows highlight nanogel uptake pathways.
